Resonate Blends, Inc. (KOAN)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Resonate Blends, Inc. (KOAN) with AI Score 62/100 (Hold). APOLLO BioWellness Inc. focuses on regenerative medicine, marketing natural stem cell mobilizing agents and diet aids. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Resonate Blends, Inc. (KOAN) Healthcare & Pipeline Overview
APOLLO BioWellness Inc., operating in the healthcare sector, focuses on regenerative medicine, marketing stem cell mobilizing agents and diet aids. With a small team and negative profitability, the company navigates the competitive landscape of specialty and generic drug manufacturing, emphasizing research and development for future growth.
Investment Thesis
Investing in APOLLO BioWellness Inc. (KOAN) presents a high-risk, high-reward scenario. The company's focus on regenerative medicine and natural stem cell mobilization offers potential in a growing market. However, with a market capitalization of $0.00B and a negative P/E ratio of -0.17, the company's financial stability is questionable. The high gross margin of 70.0% is promising, but the negative profit margin of -120.0% raises concerns about operational efficiency. Key catalysts include successful development and marketing of its stem cell mobilizing agents and diet aids. The high beta of 3.77 indicates significant volatility. Investors should carefully consider the risks associated with OTC-traded companies and the company's limited financial resources.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.00B indicating a micro-cap company with limited resources.
- P/E Ratio of -0.17 reflecting negative earnings and potential overvaluation.
- Gross Margin of 70.0% suggesting strong pricing power and efficient cost of goods sold.
- Profit Margin of -120.0% indicating significant operational inefficiencies or high operating costs.
- Beta of 3.77 indicating high volatility compared to the market.
Competitors & Peers
Strengths
- Focus on regenerative medicine, a growing field.
- Patent-pending stem cell mobilizing agents.
- License to market a dual-acting diet aid.
- Research and development activities for future products.
Weaknesses
- Small market capitalization ($0.00B).
- Negative profit margin (-120.0%).
- Limited number of employees (6).
- OTC market listing indicates higher risk.
Catalysts
- Upcoming: Successful clinical trials of stem cell mobilizing agents could drive market adoption.
- Upcoming: Regulatory approvals for new products in the regenerative medicine field.
- Upcoming: Strategic partnerships with larger pharmaceutical companies to expand market reach.
- Ongoing: Research and development efforts to create new and innovative products.
- Ongoing: Marketing and sales initiatives to increase awareness and adoption of existing products.
Risks
- Potential: Intense competition from established pharmaceutical companies.
- Potential: Stringent regulatory requirements and potential delays in approvals.
- Potential: Product liability claims and potential recalls.
- Ongoing: Limited financial resources and potential need for additional funding.
- Ongoing: High beta (3.77) indicates significant price volatility.
Growth Opportunities
- Expansion of Stem Cell Mobilizing Agent Market: The market for stem cell therapies is projected to reach $17.2 billion by 2028, growing at a CAGR of 14.5%. APOLLO BioWellness can capitalize on this growth by expanding its marketing efforts for its licensed stem cell mobilizing agents. Successful clinical trials and positive patient outcomes could drive adoption and increase revenue. The timeline for significant market penetration is estimated at 3-5 years, contingent on regulatory approvals and market acceptance.
- Development of Secretogogue Products: The market for growth hormone-related therapies is expected to grow as the population ages. APOLLO BioWellness's research and development in Secretogues, aimed at enhancing natural growth hormone production, presents a significant growth opportunity. Successful development and clinical validation of these products could lead to a new revenue stream. The timeline for commercialization is estimated at 5-7 years, given the need for extensive research and clinical trials.
- Strategic Partnerships and Licensing Agreements: APOLLO BioWellness can pursue strategic partnerships with larger pharmaceutical companies to expand its reach and access resources. Licensing agreements for its patented technologies and formulations can generate revenue and reduce the financial burden of research and development. These partnerships can provide access to established distribution networks and marketing expertise. The timeline for securing such partnerships is estimated at 1-2 years.
- Expansion into International Markets: The global market for regenerative medicine is expanding, with significant growth potential in emerging markets. APOLLO BioWellness can explore opportunities to expand its operations into international markets, particularly in Asia and Europe. This expansion can diversify its revenue streams and reduce its reliance on the US market. The timeline for international expansion is estimated at 3-5 years, contingent on regulatory approvals and market conditions.
- Development of Novel Drug Delivery Systems: Investing in novel drug delivery systems can enhance the efficacy and bioavailability of APOLLO BioWellness's products. This can lead to improved patient outcomes and increased market demand. The development of innovative delivery systems can differentiate the company from its competitors and create a competitive advantage. The timeline for developing and implementing new drug delivery systems is estimated at 2-4 years.
Opportunities
- Expansion of stem cell therapy market.
- Development of Secretogogue products.
- Strategic partnerships and licensing agreements.
- Expansion into international markets.
Threats
- Intense competition in the pharmaceutical industry.
- Stringent regulatory requirements.
- Pricing pressures on generic drugs.
- Potential for product liability claims.
Competitive Advantages
- Patented stem cell mobilizing agents provide a degree of exclusivity.
- Focus on natural formulations differentiates them from traditional pharmaceuticals.
- Research and development efforts create potential for future innovation.
- License to market a dual-acting diet aid provides a unique product offering.
About KOAN
APOLLO BioWellness Inc., based in North Bergen, New Jersey, is engaged in the discovery, development, and marketing of products in the field of regenerative medicine. The company focuses on marketing licensed, patent-pending natural stem cell mobilizing agents designed to enhance an individual's ability to mobilize their own adult stem cells from their bone marrow. Additionally, APOLLO BioWellness holds a license to market a dual-acting, all-natural diet aid intended to help control hunger through normal body signals to the brain and stomach. The company's activities also include research and development, exploring areas such as Secretogues to enhance a person's own growth hormone production and similar natural bioactive formulations to enhance human performance, utilizing known body mechanisms without the use of drugs. APOLLO BioWellness aims to innovate in the regenerative medicine space by leveraging natural compounds and formulations to improve human health and performance. The company operates with a small team of 6 employees.
What They Do
- Discovers products for regenerative medicine.
- Develops products for regenerative medicine.
- Markets products for regenerative medicine.
- Focuses on natural stem cell mobilizing agents.
- Markets a dual-acting, all-natural diet aid.
- Conducts research and development on Secretogues.
- Develops natural bioactive formulations to enhance human performance.
Business Model
- Licenses patent-pending natural stem cell mobilizing agents.
- Markets licensed diet aids.
- Conducts research and development to create new products.
- Aims to enhance human performance through natural bioactive formulations.
Industry Context
APOLLO BioWellness Inc. operates within the specialty and generic drug manufacturing industry, a segment characterized by intense competition and stringent regulatory requirements. The market is driven by an aging population, increasing prevalence of chronic diseases, and rising healthcare expenditure. Companies like APOLLO BioWellness face competition from established generic drug manufacturers and innovative biotech firms. The industry is also subject to pricing pressures and regulatory scrutiny, impacting profitability and growth prospects. APOLLO BioWellness's focus on regenerative medicine positions it in a niche market with potential for high growth but also significant risks.
Key Customers
- Individuals seeking regenerative medicine solutions.
- Individuals looking for natural stem cell mobilization.
- Individuals seeking natural diet aids.
- Healthcare providers recommending regenerative medicine products.
Financials
Chart & Info
Resonate Blends, Inc. (KOAN) stock price: Price data unavailable
Latest News
-
MedWell Ai Executes Letter Of Intent To Create America's First Vertically Integrated Regenerative Wellness Eco-System
Yahoo! Finance: KOAN News · Feb 10, 2026
-
MedWell Ai Executes Letter Of Intent To Create America's First Vertically Integrated Regenerative Wellness Eco-System
GlobeNewswire · Feb 10, 2026
-
Apollo Biowellness Executes Letter Of Intent with Medwell AI, Inc.
TMX Newsfile · Feb 10, 2026
-
Apollo Biowellness Executes Letter Of Intent with Medwell AI, Inc.
newsfilecorp.com · Feb 10, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for KOAN.
Price Targets
Wall Street price target analysis for KOAN.
MoonshotScore
What does this score mean?
The MoonshotScore rates KOAN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
MedWell Ai Executes Letter Of Intent To Create America's First Vertically Integrated Regenerative Wellness Eco-System
MedWell Ai Executes Letter Of Intent To Create America's First Vertically Integrated Regenerative Wellness Eco-System
Apollo Biowellness Executes Letter Of Intent with Medwell AI, Inc.
Apollo Biowellness Executes Letter Of Intent with Medwell AI, Inc.
Leadership: James W. Zimbler
Unknown
Information on James W. Zimbler's background is not available in the provided data. Further research would be needed to determine his career history, education, and previous roles.
Track Record: Information on James W. Zimbler's track record is not available in the provided data. Further research would be needed to determine his key achievements, strategic decisions, and company milestones under his leadership.
KOAN OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that APOLLO BioWellness Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosures and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Low trading volume and wide bid-ask spreads can lead to price volatility.
- Potential for fraud or manipulation is higher in the OTC market.
- OTC Other tier companies may have difficulty raising capital.
- Lack of regulatory oversight increases investment risk.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Check for any legal or regulatory issues involving the company.
- Monitor the company's news releases and public statements.
- Consult with a financial advisor before investing.
- Engagement in research and development activities.
- Possession of patents or licenses for its products.
- Focus on regenerative medicine, a legitimate field.
- Operation for a number of years.
Resonate Blends, Inc. Stock: Key Questions Answered
What does Resonate Blends, Inc. do?
APOLLO BioWellness Inc. (KOAN) operates in the healthcare sector, focusing on regenerative medicine. The company develops, discovers, and markets products, including licensed patent-pending natural stem cell mobilizing agents designed to enhance an individual's ability to mobilize their own adult stem cells from their bone marrow. Additionally, they market a dual-acting, all-natural diet aid intended to help control hunger. The company also conducts research and development activities, exploring areas such as Secretogues to enhance a person's own growth hormone production.
What do analysts say about KOAN stock?
There is currently no available analyst coverage or consensus on APOLLO BioWellness Inc. (KOAN) due to its small market capitalization and OTC listing. Investors should conduct their own thorough due diligence and consider the risks associated with investing in micro-cap, OTC-traded companies. Key valuation metrics such as P/E ratio (-0.17) and profit margin (-120.0%) indicate financial challenges. Growth considerations include successful development and marketing of its products and potential partnerships.
What are the main risks for KOAN?
APOLLO BioWellness Inc. (KOAN) faces several risks, including intense competition in the pharmaceutical industry, stringent regulatory requirements, and potential delays in product approvals. The company's limited financial resources and negative profit margin raise concerns about its ability to sustain operations and fund future growth. The OTC listing increases the risk of low liquidity and price volatility. Additionally, potential product liability claims and recalls could negatively impact the company's financial performance and reputation.
What are the key factors to evaluate for KOAN?
Resonate Blends, Inc. (KOAN) currently holds an AI score of 62/100, indicating moderate score. Key strength: Focus on regenerative medicine, a growing field.. Primary risk to monitor: Potential: Intense competition from established pharmaceutical companies.. This is not financial advice.
How frequently does KOAN data refresh on this page?
KOAN prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven KOAN's recent stock price performance?
Recent price movement in Resonate Blends, Inc. (KOAN) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focus on regenerative medicine, a growing field.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider KOAN overvalued or undervalued right now?
Determining whether Resonate Blends, Inc. (KOAN) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying KOAN?
Before investing in Resonate Blends, Inc. (KOAN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on OTC-traded companies.
- Financial data may not be fully reliable due to limited disclosure requirements.